Medicinal composition of 24-methylene cycloartenyl ferulate

A technology of pineapple ferulate and methylene cyclowood, which is applied in the field of medicine and can solve the problems of inability to solve the problem of solubilization and low solubility of 24-methylene cycloartene ferulate

Active Publication Date: 2011-07-20
BEIJING CENTURY BIOCOM PHARMA TECH
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the research on the pure product of 24-methylene cycloartenol ferulate, the applicant found that its solubility in water is lower than that of oryzanol raw materials, only about 1 / 4 of the solubility of oryzanol, and the traditional solubilization schemes are all Unable to solve the problem of solubilization of 24-methylene cycloartenol ferulate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition of 24-methylene cycloartenyl ferulate
  • Medicinal composition of 24-methylene cycloartenyl ferulate
  • Medicinal composition of 24-methylene cycloartenyl ferulate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Take 20g of s40, heat it to a molten state at 60°C, then add 4g of 24-methylene cycloartenyl ferulic acid ester to it, mix and stir for 30min, add the obtained molten liquid into 5L of water for injection and stir until completely dissolved , the obtained pharmaceutical composition of the present invention, the concentration is 0.8mg / ml.

[0029] The resulting solution cleared completely on standing at room temperature for 24 hours.

[0030] The obtained pharmaceutical composition solution is filtered with a 0.45um filter membrane, and after passing the test, it is packed into an oral liquid bottle to obtain 400 oral preparations of the pharmaceutical composition of the present invention.

Embodiment 2

[0032]Take 100g of s32, heat it to a molten state at 60°C, then add 5g of 24-methylene cycloartenyl ferulic acid ester to it, mix and stir for 50min, add the obtained molten liquid into 3L of water for injection and stir until completely dissolved , the obtained pharmaceutical composition of the present invention, the concentration is 0.7mg / ml.

[0033] The resulting solution cleared completely on standing at room temperature for 24 hours.

[0034] The obtained pharmaceutical composition solution was stirred with 0.3% active carbon for injection for 30 minutes, decarbonized and filtered, and finely filtered through a 0.22um microporous filter membrane, then packed into vials to obtain 500 injections of the pharmaceutical composition of the present invention.

Embodiment 3

[0036] Take 200g of s40, heat it to a molten state at 70°C, then add 4g of 24-methylene cycloartenyl ferulic acid ester to it, mix and stir for 30min, add the resulting molten liquid to 4L of water for injection and stir until completely Dissolved to obtain the pharmaceutical composition of the present invention with a concentration of 1 mg / ml.

[0037] The resulting solution cleared completely on standing at room temperature for 24 hours.

[0038] The above pharmaceutical composition solution was added with 0.3% activated carbon for injection and stirred for 30 minutes. After decarburization and filtration, after fine filtration with a 0.22um microporous membrane, the following freeze-drying process was adopted:

[0039] Pre-freezing: The temperature of the product drops to -45°C, and it can be sublimated and dried after 3 hours of heat preservation;

[0040] Sublimation drying: the sublimation drying temperature is controlled below -12°C;

[0041] Re-drying: the maximum te...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicinal composition of 24-methylene cycloartenyl ferulate, which solves the problem that the 24-methylene cycloartenyl ferulate is slightly soluble in water. The medicinal composition comprises the 24-methylene cycloartenyl ferulate and polyoxyl stearate; and a stable and water-soluble oryzanol medicinal composition solution is obtained by adding the 24-methylene cycloartenyl ferulate into the fused polyoxyl stearate. The invention also discloses a preparation method of the medicinal composition solution and preparation application.

Description

technical field [0001] The invention discloses a pharmaceutical composition of 24-methylene cycloartenol ferulate, which comprises 24-methylene cycloartenol ferulate and polyoxyl stearate, and belongs to the field of medicine . Background technique [0002] Oryzanol is a natural mixture composed of cycloartenol ferulic acid esters and sterol ferulic acid esters. The main two components are cycloartenol ferulic acid esters and 24 - Methyl cycloartenol ferulate, the content of the two in unpurified oryzanol is about 70%, and it is the main active ingredient in oryzanol. Long-term studies have found that oryzanol has a variety of pharmacological activities, such as lowering blood lipids, lowering cholesterol absorption, preventing lipid oxidation, preventing cardiovascular diseases, alleviating various physical obstacles and autonomic nervous disorders in women after menopause, and improving diencephalon function out of tune. [0003] In the existing technical schemes, oryza...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61K47/34A61P25/00A61P15/12A61P9/00A61K47/10A61K47/26A61K47/44
Inventor 郝守祝
Owner BEIJING CENTURY BIOCOM PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products